Unlock instant, AI-driven research and patent intelligence for your innovation.
Crystalline ledipasvir compound and process for its preparation
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of solvate and acetonate, which is applied in the field of medicine and achieves the effects of less degraded impurities, stable crystal form and favorable storage.
Inactive Publication Date: 2017-10-27
NANJING CHIA TAI TIANQING PHARMA +1
View PDF2 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0003] Sofosbuvir is a nucleoside NS5B polymerase inhibitor prodrug developed by Gilead. It is the first anti-hepatitis C drug that can be used without interferon. It has been approved in combination with ribavirin for gene 2 , type 3 hepatitis C patients, but for patients with genotype 1 hepatitis C, sofosbuvir still needs to be used in combination with interferon
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0028] Example 1: Preparation of Ledipavir Hemiacetone Solvate
[0029] Take 2.0 g of Radipavir diacetone hydrate, add 20 mL of n-heptane, and stir at 25-30°C for 5 hours. After filtration, the obtained solid was rinsed with n-heptane, and the solid was dried in a blast drying oven at 50° C. for 4 hours to obtain 1.6 g of light yellow solid.
[0030] The obtained light yellow solid proton nuclear magnetic resonance spectrum detection diagram is attached figure 1 , Attached figure 2 As shown, the peak of chemical shift 2.09 is a characteristic peak of acetone, which is 3.06H after integration, indicating that acetone and Ledipavir molecules form a complex with a molecular ratio of 1:2.
[0031] XRPD inspection chart is attached image 3 Shown.
[0032] Instruments and test conditions used for XRPD testing:
[0033] Instrument: Bruker d8 advance X-ray diffractometer
[0034] Test conditions: test current and voltage: 40kv / 40mA, detector: lyxEye, test step: 0.01°
[0035] Target type: Cu ...
Embodiment 2
[0036] Example 2: Preparation of Ledipavir Hemiacetone Solvate
[0037] Take 2.0 g of Radipavir diacetone hydrate, add 30 mL of n-hexane, and stir at 25-30°C for 4 hours. After filtration, the obtained solid was rinsed with n-hexane, and the solid was dried in a blast drying oven at 40° C. for 5 hours to obtain 1.5 g of a light yellow solid.
[0038] After testing, its proton nuclear magnetic resonance spectrum detection chart and XRPD detection chart are consistent with the product of Example 1.
Embodiment 3
[0039] Example 3: Preparation of Ledipavir Hemiacetone Solvate
[0040] Take 2.0 g of Radipavir diacetone hydrate, add 20 mL of petroleum ether, and stir at 25-30°C for 5 hours. After filtration, the obtained solid was rinsed with petroleum ether, and the solid was dried in a blast drying oven at 25° C. for 6 hours to obtain 1.6 g of light yellow solid.
[0041] After testing, its proton nuclear magnetic resonance spectrum detection chart and XRPD detection chart are consistent with the product of Example 1.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a crystallized Ledipasvir compound, a preparation method therefor and a pharmaceutical composition comprising the crystallized Ledipasvir compound. The crystallized Ledipasvir compound provided by the invention has characteristics of being high in stability and beneficial for drying materials and transporting on production, and is suitable for being used as a bulk pharmaceutical chemical in industry. The invention further provides a preparation method for the crystallized Ledipasvir compound, and the preparation method is simple to operate and high in yield. A pharmaceutical composition comprising the crystallized Ledipasvir compound provided by the invention can be used for treating hepatitis c.
Description
Technical field [0001] The invention belongs to the technical field of medicine, and relates to Ledipavir semiacetone compound and its crystal form, a preparation method, a pharmaceutical composition containing it, and an application thereof. Background technique [0002] Hepatitis C (CHC) is a viral hepatitis caused by hepatitis C virus (HCV) infection. It is mainly spread through blood transfusion, acupuncture, drug use, etc. According to the World Health Organization, about 180 million people worldwide are infected with HCV. There are approximately 3 to 4 million new cases of hepatitis C each year. [0003] Sofosbuvir is a nucleoside NS5B polymerase inhibitor prodrug developed by Gilead. It is the first anti-hepatitis C drug that can be used without interferon. It has been approved in combination with ribavirin for gene 2 , 3 type hepatitis C patients, but for genotype 1 hepatitis C patients, sofosbuvir still needs to be used in combination with interferon. [0004] Sofosbuvir / L...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.